EPAS1
Endothelial PAS domain-containing protein 1
As of the edition of 20 October 2026, EPAS1 (endothelial PAS domain-containing protein 1, UniProt Q99814) has 5 drugs tested at it and 9 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q99814
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 44
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Inherited and neonatal; Nervous system; Hormones; Digestive system
- Registered trials of its drugs
- 57
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Stopped | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Belzutifan | Marketed | Phase 3 | Ends 2034 |
| Casdatifan | Active | Phase 3 | none listed |
| NKT2152 | Active | Phase 2 | none listed |
| AB521 | Stopped | Phase 1 | none listed |
| DFF332 | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 5 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Novartis | Route A |
| Exelixis | Route A |
The other 6 companies at EPAS1
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at EPAS1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.